Metabolism and disposition of hepatitis C polymerase inhibitor dasabuvir in humans

Drug Metabolism and Disposition

Volumn 44, Issue 8, 2016, Pages 1139-1147

  Shen, Jianwei ^a   Serby, Michael ^a   Reed, Aimee ^a   Lee, Anthony J ^a   Menon, Rajeev ^a   Zhang, Xiaomei ^a   Marsh, Kennan ^a   Wan, Xia ^a   Kavetskaia, Olga ^a,b   Fischer, Volker ^a  

^a ABBVIE INC   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DASABUVIR; DRUG METABOLITE; GLUCURONIDE; SULFATE; ABT-333; ANTIVIRUS AGENT; ENZYME INHIBITOR; NS-5 PROTEIN, HEPATITIS C VIRUS; SULFONAMIDE; URACIL; VIRAL PROTEIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; DRUG TRANSFORMATION; FECES; GLUCURONIDATION; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIQUID SCINTILLATION COUNTING; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; RADIOACTIVITY; SINGLE DRUG DOSE; SULFATION; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOTRANSFORMATION; BLOOD; CHEMISTRY; DRUG ADMINISTRATION; DRUG EFFECTS; ENZYMOLOGY; HEPACIVIRUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROXYLATION; METABOLISM; OXIDATION REDUCTION REACTION; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

ANTIVIRAL AGENTS; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FECES; GLUCURONIDES; HEALTHY VOLUNTEERS; HEPACIVIRUS; HUMANS; HYDROXYLATION; MALE; OXIDATION-REDUCTION; SULFATES; SULFONAMIDES; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; URACIL; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84978069596     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.067512     Document Type: Article

References (12)

1. Beaulieu PL (2009) Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection. Expert Opin Ther Pat 19:145-164.
2. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, and Pilot-Matias T, et al. (2014) Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370:1594-1603.
3. Fisher MB, Campanale K, Ackermann BL, VandenBranden M, and Wrighton SA (2000) In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 28:560-566.
4. Hamilton RA, Garnett WR, and Kline BJ (1981) Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408-413.
5. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, Kwo P, Foster GR, and Sulkowski MS, et al. (2014) Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 370:222-232.
6. Legrand-Abravanel F, Nicot F, and Izopet J (2010) New NS5B polymerase inhibitors for hepatitis C. Expert Opin Investig Drugs 19:963-975.
7. Maring C, Wagner R, Hutchinson D, Flentge C, Kati W, Koev G, Liu Y, Beno D, Shen J, and Lau YY, et al. (2009) Preclinical potency, pharmacokinetic and adme characterization of ABT-333, a novel non-nucleoside HCV polymerase inhibitor. J Hepatol 50 (Suppl 1):S347.
8. Menon RM, Badri P, Das U, Wang T, Polepally A, Khatri A, Wang H, Coakely E, Podsadecki T, Awni W, et al. (2014) Drug-drug interactions with direct acting antiviral combination therapy of ABT-450/r, ombitasvir and dasabuvir, in Proceedings of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2014 September 5-9; Washington, DC. pp A-007, American Society for Microbiology, Washington, DC.
9. Moradpour D, Penin F, and Rice CM (2007) Replication of hepatitis C virus. Nat Rev Microbiol 5:453-463.
10. Rigat K, Wang Y, Hudyma TW, Ding M, Zheng X, Gentles RG, Beno BR, Gao M, and Roberts SB (2010) Ligand-induced changes in hepatitis C virus NS5B polymerase structure. Antiviral Res 88:197-206.
11. Zenser TV, Lakshmi VM, and Davis BB (1999) Human and Escherichia coli beta-glucuronidase hydrolysis of glucuronide conjugates of benzidine and 4-aminobiphenyl, and their hydroxy metabolites. Drug Metab Dispos 27:1064-1067.
12. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, and Desmond P, et al. (2014) Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370:1604-1614.